Tag: Autobahn Therapeutics
-
Autobahn Therapeutics Unveils Preclinical Data Supporting Restorative Neuroplasticity Mechanism of Elunetirom
New Preclinical Findings Spotlight a Restorative Neuroplasticity Mechanism Autobahn Therapeutics has presented new preclinical data for its investigational drug, Elunetirom, at the American College of Neuropsychopharmacology (ACNP) Annual Meeting. The research centers on a novel restorative neuroplasticity mechanism believed to promote recovery and resilience in neuropsychiatric and neuroimmunologic disorders. The findings add to the company’s…
-
Autobahn Therapeutics Unveils Preclinical Data on Elunetirom’s Restorative Neuroplasticity at ACNP Annual Meeting
Autobahn Therapeutics Highlights New Preclinical Data on Elunetirom Autobahn Therapeutics, a pioneering biotechnology company focused on restorative treatments for neuropsychiatric and neuroimmunologic disorders, announced new preclinical findings for elunetir… at the American College of Neuropsychopharmacology (ACNP) annual meeting. The presentation contributes to growing evidence that elunetirom could drive restorative neuroplasticity, a therapeutic paradigm aimed at…
-
Autobahn Therapeutics Presents Elunetirom Preclinical Data Supporting Restorative Neuroplasticity at ACNP
Autobahn Therapeutics Shares Promising Preclinical Elunetirom Data at ACNP Autobahn Therapeutics, a biotechnology company focused on restorative treatments for neuropsychiatric and neuroimmunologic disorders, announced new preclinical data on its lead compound, elunetir… (truncated press release content) The company’s presentation at the American College of Neuropsychopharmacology (ACNP) annual meeting underscores a novel mechanism of action for…